Increased glucose utilization by the tumor but also due to secretion of insulin analogues Severe hepatic disease such as hepatitis, cirrhosis, neoplasia, amyloidosis, hepatotoxinsĭecreased glucose production from lack of a counter-regulatory hormone (i.e., cortisol)ĭecreased glucose production from lack of a counter-regulatory hormone (i.e., growth hormone or adrenocorticotropic hormone)Įxcess glucose utilization due to hypersecretion of insulinĮxtra-pancreatic tumors (e.g., hepatocellular carcinoma, hepatoma, leiomyosarcoma, leiomyoma) Beta blockers via suspected interference of counter- regulatory mechanisms Inadequate intake and depletion of glycogen storesĭrug and toxin associated causes such as iatrogenic insulin overdose, xylitol toxicity, oral hypoglycemic agents (usually sulfonylureas), beta blockersĮxcess glucose utilization due to hypersecretion of insulin and increased tissue sensitivity to insulin. Inadequate glycogen stores, limited fat and muscle mass Neonatal/juvenile or toy breed juvenile hypoglycemia Extreme exercise (e.g., hunting dog hypoglycemia)Įxcess glucose utilization and inadequate glycogen stores
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |